A clinical study to investigate the potential of an engineered human monoclonal antibody, HCTMO1, for immunotherapy of ovarian cancer:

T. J. Broadhead,Q. Davies,A. C. van Hof,C. F. M. Molthoff,A. C. Perkins,J. C. Roos, W. M. Prinssen,R. H. M. Verheijen,W. den Hollander,M. Sopwith,M. Frier,P. Kenemans, L. M. Symonds

Nuclear Medicine Communications（1997）

Cited 0|Views7

No score

Abstract

Broadhead, T. J.1; Davies, Q.1; van Hof, A. C.2; Molthoff, C. F.M.2; Perkins, A. C.1; Roos, J. C.2; Prinssen, W. M.2; Verheijen, R. H.M.2; den Hollander, W.2; Sopwith, M.3; Frier, M.1; Kenemans, P.2; Symonds, L. M.1 Author Information

Translated text

Key words

monoclonal antibody

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined